<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812174</url>
  </required_header>
  <id_info>
    <org_study_id>2010-01</org_study_id>
    <secondary_id>G120115</secondary_id>
    <nct_id>NCT01812174</nct_id>
  </id_info>
  <brief_title>On-X Heart Valve - 17mm Aortic and 23mm Mitral</brief_title>
  <official_title>On-X Heart Valve - 17mm Aortic and 23mm Mitral</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>On-X Life Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>On-X Life Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the hemodynamic and hemolytic properties of two additional smaller size
      valves to the On-X line of valves already approved by FDA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to assess the safety and efficacy of the 17mm On-X Aortic
      Prosthetic Heart Valve and the 23mm On-X Mitral Prosthetic Heart Valve when used to replace
      diseased aortic or mitral valves in human subjects.

      The On-X 17mm aortic and 23mm mitral valves will be implanted in approximately 20 and at
      least 15 patients per size and each will be followed for at least 1 year. Patients will be
      any age and will require these size valves as determined in surgery but will be recruited
      prior to surgery based on results of preoperative screening tests.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients in one arm are recipients of the 17mm On-X Aortic Valve. Patients in the second arm are recipients of the 23mm On-X Mitral Valve. Since double valve cases are exclusionary, these two arms are mutually exclusive and non-randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamics as a measure of performance</measure>
    <time_frame>1-year</time_frame>
    <description>Pressure gradient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Valve-related adverse events as a measure of safety</measure>
    <time_frame>1-year</time_frame>
    <description>Composite rate of thromboembolism, bleeding, structural dysfunction, endocarditis, non-structural dysfunction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>17mm On-X Aortic Heart Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>23mm On-X Mitral Heart Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>17mm aortic valve (On-X )</intervention_name>
    <description>Heart aortic valve replacement surgery: 17mm Aortic</description>
    <arm_group_label>17mm On-X Aortic Heart Valve</arm_group_label>
    <other_name>On-X prosthetic heart valve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>23mm mitral valve (On-X)</intervention_name>
    <description>Heart mitral valve replacement surgery: 23mm Mitral</description>
    <arm_group_label>23mm On-X Mitral Heart Valve</arm_group_label>
    <other_name>On-X prosthetic heart valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of any age; unless waived by local IRB assent of the patient and in all cases
             consent of parent or legally authorized representative is required if a patient is
             under the age of majority and not legally emancipated.

          2. Patients who are sufficiently ill to warrant replacement of their diseased natural or
             prosthetic valve, based on standard cardiovascular diagnostic workups.

          3. Patients who are in sufficient satisfactory condition, based on the physical exam and
             investigator's experience, to be an average or better operative risk, (i.e., likely to
             survive one year postoperatively).

          4. Patients who require an isolated aortic valve replacement size 17 mm or isolated
             mitral valve replacement size 23mm.

          5. Patients who are geographically stable and willing to return to the implanting center
             for follow-up visits.

          6. Patients or legally authorized representatives who are adequately informed of their
             participation in the clinical study and what will be required of them in order to
             comply with the protocol.

          7. Patients requiring concomitant cardiovascular surgery, such as coronary bypass may be
             included in the study.

        Exclusion Criteria:

        1. Patients who are pregnant, planning to become pregnant or are lactating. 2 Patients who
        have a noncardiac progressive disease, which in the investigator's experience produces an
        unacceptable increased risk to the patient.

        3 Patients who have a documented history of substance (drug or alcohol) abuse or are prison
        inmates.

        4. Patients with a previous prosthetic valve, where it is not being replaced by a study
        valve, or patients requiring multiple valve replacement.

        5. Patients with active endocarditis or active myocarditis. 6 Patients who require
        tricuspid or pulmonic valve replacement. 7. Patients who have not agreed to return for the
        required number of follow-up visits or who are geographically unavailable for follow-up.

        8. Patients who cannot be maintained on long-term anticoagulant therapy. 9. Patients with
        non-cardiac illness resulting in a life expectancy of less than 1-year.

        10. Patients previously enrolled and implanted in this trial may not re-enter after
        withdrawal.

        11. Patients already enrolled in another investigational device or drug study (nor can
        enrolled patients be enrolled in other studies).

        12. Patients with acute preoperative neurological deficit, myocardial infarction, or
        cardiac event who have not returned to baseline for at least 30-days prior to enrollment.

        13. Patients with aortic aneurysm or other medical condition that creates a higher than
        usual risk of surgical complication.

        14. Patients who are prisoners or mentally ill, and pediatric patients who are incapable of
        understanding their assent as judged by the principal investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney Levitsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Ottmers, PhD</last_name>
    <phone>512-339-8000</phone>
    <phone_ext>254</phone_ext>
    <email>Ottmers.Stephen@cryolife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gretchen Wilderspin, MS</last_name>
    <phone>678-290-4309</phone>
    <email>Wilderspin.Gretchen@cryolife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Lamm</last_name>
      <phone>650-962-4566</phone>
      <email>Janet_Lamm@elcaminohospital.org</email>
    </contact>
    <contact_backup>
      <last_name>Ryan Schroeder</last_name>
      <phone>650-691-4894</phone>
      <email>Ryan_Schroeder@elcaminohospital.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vincent Gaudiani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsey Gallant, BN</last_name>
      <phone>207-662-1489</phone>
      <email>BGallant@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Reed Quinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan, C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Doman</last_name>
      <phone>734-763-6109</phone>
      <email>tpaterso@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nichole Rottach</last_name>
      <email>nrottach@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ming-Sing Si, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Ohye, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Bove, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Romano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jimmy Lu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Heart Center Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ciccolo, MD</last_name>
      <phone>702-732-1290</phone>
      <email>michaelciccolo@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Shalethia Turner</last_name>
      <phone>702-990-4812</phone>
      <phone_ext>1601</phone_ext>
      <email>sturner@childrensheartcenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Ciccolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Carrillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Morales, MD</last_name>
      <phone>513-803-9150</phone>
      <email>David.Morales@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Tricia Heile</last_name>
      <phone>513-803-5267</phone>
      <email>Tricia.Heile@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roosevelt Bryant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Byrnes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Taylor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Kwiatkowski, MD</last_name>
      <phone>614-355-6788</phone>
      <email>Pawel.Kwiatkowski@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Patrick McConnell, MD</last_name>
      <phone>614-722-3102</phone>
      <email>Patrick.McConnell@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick McConnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma/Children's Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Burkhart, MD</last_name>
      <phone>405-271-2601</phone>
      <email>harold-burkhart@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Lander</last_name>
      <phone>405-271-2601</phone>
      <email>theresa-lander@ouhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Harold Burkhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Dallas Children's</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Pirolli, MD</last_name>
      <phone>214-456-5000</phone>
      <email>Timothy.Pirolli@UTSouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Bowling</last_name>
      <phone>214-456-2810</phone>
      <email>Angela.Bowling@childrens.com</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Pirolli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Gangemi, MD</last_name>
      <phone>434-924-9061</phone>
      <email>JJG5D@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachael Simon, BSN</last_name>
      <phone>434-2437653</phone>
      <email>RMG5R@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Gangemi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's - Tacoma General Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Nichols, MD</last_name>
      <phone>253-403-7257</phone>
      <email>dennis.nichols@multicare.org</email>
    </contact>
    <contact_backup>
      <last_name>Janey Barnhart</last_name>
      <phone>253-403-7252</phone>
      <email>Meredith.Barnhart@multicare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Dennis Nichols, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayaguez Medical Center</name>
      <address>
        <city>Mayaguez</city>
        <zip>00681</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Garcia-Rinaldi, MD</last_name>
      <phone>787-538-0019</phone>
      <email>garciarinaldi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Raul Garcia-Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

